文献速递脑血管病

TAK1依赖的小胶质细胞和巨噬细胞反应加重缺血性卒中远期结局

Transforming Growth Factor Beta-Activated Kinase 1-Dependent Microglial and Macrophage Responses Aggravate Long-Term Outcomes After Ischemic Stroke.
PubMed 文献 · Stroke · 2020-02-12

该研究在小鼠大脑中动脉闭塞再灌注模型中,通过小胶质细胞/巨噬细胞特异性敲除TAK1或使用抑制剂5Z-7-Oxozeaenol干预,发现TAK1促进促炎性小胶质细胞/巨噬细胞反应,加重神经炎症和长期脑损伤,抑制TAK1可改善远期神经功能与认知结局。

要点

  • TAK1是小胶质细胞/巨噬细胞促炎表型的关键驱动因子。
  • 抑制TAK1可减轻卒中后神经炎症和长期灰白质损伤。
  • 缺血再灌注后2小时开始抑制TAK1仍能改善远期功能。

核心结论

  • TAK1通过增强促炎性和有害的小胶质细胞/巨噬细胞反应,促进缺血再灌注诱导的炎症、脑损伤和适应不良行为。
  • 抑制TAK1是改善卒中远期结局的有前景的治疗策略。

研究设计与样本

  • 年轻成年小鼠接受1小时大脑中动脉闭塞(MCAO)后再灌注。
  • 通过他莫昔芬诱导的小胶质细胞/巨噬细胞特异性敲除或MCAO后给予选择性抑制剂5Z-7-Oxozeaenol靶向TAK1。
  • 评估至MCAO后35天的神经行为缺陷及长期灰质和白质损伤。
  • MCAO后3天通过RNA-seq、流式细胞术和免疫组化评估小胶质细胞/巨噬细胞功能状态和脑炎症特征。

主要发现

  • TAK1小胶质细胞/巨噬细胞特异性敲除在MCAO后至少35天内显著改善转棒和圆筒实验中的神经行为缺陷。
  • RNA-seq显示,与WT小鼠相比,TAK1敲除小鼠MCAO后3天纯化的小胶质细胞和巨噬细胞中促炎基因及其预测生物学功能下调或受抑制。
  • Oxozeaenol治疗减轻MCAO后3天神经炎症,表现为Iba1+/CD16+促炎小胶质细胞/巨噬细胞减少及外周免疫细胞脑内浸润受抑。
  • MCAO后2小时开始Oxozeaenol治疗改善了足误、转棒和水迷宫实验中的长期感觉运动和认知功能。
  • Oxozeaenol在MCAO后35天促进灰质和白质完整性。

临床怎么用

  • TAK1可能作为缺血性卒中后抗炎治疗的潜在靶点。
  • 小胶质细胞/巨噬细胞特异性TAK1抑制或选择性抑制剂可能改善卒中远期神经功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Microglia/macrophages (Mi/MΦ) can profoundly influence stroke outcomes by acquiring functionally dominant phenotypes (proinflammatory or anti-inflammatory; deleterious or salutary). Identification of the molecular mechanisms that dictate the functional status of Mi/MΦ after brain ischemia/reperfusion may reveal novel therapeutic targets for stroke. We hypothesized that activation of TAK1 (transforming growth factor beta-activated kinase 1), a key MAP3K upstream of multiple inflammation-regulating pathways, drives Mi/MΦ toward a proinflammatory phenotype and potentiates ischemia/reperfusion brain injury. Methods- Young adult mice were subjected to 1 hour of middle cerebral artery occlusion (MCAO) followed by reperfusion. TAK1 was targeted by tamoxifen-induced Mi/MΦ-specific knockout or administration of a selective inhibitor 5Z-7-Oxozeaenol after MCAO. Neurobehavioral deficits and long-term gray matter and white matter injury were assessed up to 35 days after MCAO. Mi/MΦ functional status and brain inflammatory profiles were assessed 3 days after MCAO by RNA-seq, flow cytometry, and immunohistochemistry. Results- TAK1 Mi/MΦ-specific knockout markedly ameliorated neurological deficits in the rotarod and cylinder tests for at least 35 days after MCAO. Mechanistically, RNA-seq of purified brain Mi/MΦ demonstrated that proinflammatory genes and their predicted biological functions were downregulated or inhibited in microglia and macrophages from TAK1 Mi/MΦ-specific knockout mice versus WT mice 3 days after MCAO. Consistent with the anti-inflammatory phenotype of Mi/MΦ-specific knockout, oxozeaenol treatment mitigated neuroinflammation 3 days after MCAO, manifested by less Iba1+/CD16+ proinflammatory Mi/MΦ and suppressed brain invasion of various peripheral immune cells. Oxozeaenol treatment beginning 2 hours after MCAO improved long-term sensorimotor and cognitive functions in the foot fault, rotarod, and water maze tests. Furthermore, Oxozeaenol promoted both gray matter and white matter integrity 35 days after MCAO. Conclusions- TAK1 promotes ischemia/reperfusion-induced inflammation, brain injury, and maladaptive behavior by enhancing proinflammatory and deleterious Mi/MΦ responses. Therefore, TAK1 inhibition is a promising therapy to improve long-term stroke outcomes.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Wang R, Pu H, Ye Q, et al. Transforming Growth Factor Beta-Activated Kinase 1-Dependent Microglial and Macrophage Responses Aggravate Long-Term Outcomes After Ischemic Stroke. Stroke. 2020. PMID: 32078472. doi:10.1161/STROKEAHA.119.028398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。